In a rat model of obesity and impaired glucose tolerance, DPP-IV-IN-1 (0.1 and 0.3 mg/kg, p.o.) reduces the increase in plasma glucose beginning 30 min after glucose loading and significantly suppresses hyperglycemia (0.3 mg/kg). The effect is based on its inhibitory effect on plasma DPP-IV activity.